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Background andMethods:We examined the outcomes of synovial sarcoma (SS) patients in a national database. We identiﬁed 1,189 patients from
the Surveillance, Epidemiology, and End Results (SEER) database with data on site and extent of surgery. We excluded patients diagnosed before
1990, <18 years, or lacking pathologic conﬁrmation. Using Kaplan–Meier and Cox proportional hazards analyses, we determined predictors of
overall (OS) and disease‐speciﬁc survival (DSS).
Results: The mean age was 41, 49.3% were female, and 82.2% were white. Radiotherapy (RT) was administered to 57.5%. On multivariable
analysis, age at diagnosis, sex, race, anatomic site, SEER summary stage, tumor size, surgery type, and RT predicted OS. Similar predictors of DSS
were identiﬁed. The hazard ratio (HR) for OS was 0.65 (95% CI 0.48–0.88) in favor of RT and 0.62 (95% CI 0.45–0.86) for DSS. Five‐year OS
improved 8.4 1.0% with RT (P¼ 0.003), and ﬁve‐year DSS improved 7.7 1.0% with RT (P¼ 0.015).
Conclusions: In the largest study to date examining the role of RT in synovial sarcoma, we observed that RT was associated with a statistically
signiﬁcant improvement in oncologic outcome among SS patients. These data support the use of RT in the multi‐modality treatment of patients
with SS.
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INTRODUCTION
Soft tissue sarcomas (STS) represent a heterogeneous group of
mesenchymal tumors with variable clinical behavior and response to
therapy [1]. As a result, the multi‐modality treatment of STS is
increasingly subtype‐speciﬁc [2,3]. This often poses problems in
treating patients with rare subtypes since extensive data from clinical
trials and outcomes studies are often not available to guide rigorous
evidence‐based management [4].
Synovial sarcoma is one example of a rare subtype of STS,
comprising approximately 5–10% of cases [5]. It commonly occurs in
adolescents and young adults, and morphologically often resembles
small round cell sarcomas [3,6]. Consequently, it is often grouped with
pediatric soft tissue sarcomas such as rhabdomyosarcoma, Ewing’s
sarcoma, and desmoplastic small round cell sarcoma [5]. However, the
age distribution for synovial sarcoma is older than these pediatric
sarcomas, and some have questioned whether pediatric STS treatment
protocols can be extrapolated to this STS subtype [5].
As is true for other STS, important factors for outcome in synovial
sarcoma include tumor size, tumor depth, tumor location, and the ability
to achieve a complete resection [7–11]. In general, synovial sarcoma is
considered a high‐grade sarcoma with poor prognosis, and signiﬁcant
debate has focused on the role of chemotherapy in the multi‐modality
management of this disease [5,10,12,13]. As noted above, many
consider cytotoxic chemotherapy a standard component of multi‐
modality therapy [14,15]. However, the administration of adjuvant
chemotherapy for adult patients with synovial sarcoma remains
controversial since deﬁnitive evidence from randomized trials is
lacking [4,12,16]. In addition, due to the potential for overlapping
toxicities, the use of radiotherapy (RT) either sequentially or in
combination with chemotherapy in an interdigitated approach may limit
the ability to administer recommended doses of chemotherapy [17,18].
For these reasons, RT is sometimes de‐emphasized in the multi‐modality
therapy for synovial sarcoma patients, and nationally the use of
trimodality therapy to treat synovial sarcoma is low [2,6].
The objective of our study was to evaluate the role of RT in the
management of synovial sarcoma since this topic has received less
evaluation. Although surgical resection in combination with RT is
generally considered the backbone of potentially curative therapy for
locally advanced STS like synovial sarcoma, some small series have
suggested that synovial sarcoma may be resistant to RT [6,19]. Given
these concerns, we sought to examine the role of RT in a large national
database of synovial sarcoma patients. We hypothesized that synovial
sarcoma was a potentially radio‐resistant histology and that RT would
have a negligible impact on oncologic outcome.
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METHODS
Using the Surveillance, Epidemiology, and End Results (SEER)
database, we identiﬁed all cases of synovial sarcoma (ICD‐O‐3 codes
9040, 9041, 9042, and 9043) diagnosed from 1990 to 2009.We included
patients with pathologic conﬁrmation of the diagnosis and age18 years
old. We excluded patients <18 years old because of the differences in
management of pediatric and adult patients, particularly with respect to
the administration of chemotherapy and RT [20,21]. We also excluded
patients diagnosed at autopsy, patients with metastatic disease, and
patients not undergoing surgical intervention. Our cohort selection
process is depicted in Figure 1.
We then abstracted data on patient demographics, primary tumor site,
tumor size, stage at diagnosis, receipt of surgical and radiation treatment,
marital status, duration of follow‐up, vital status, and cause of death. As
the standard T and N stage information was not consistently available
over the course of the study period, we used SEER summary stage as a
surrogate variable for stage at diagnosis. We categorized surgical
therapy as radical resection (radical surgery and total removal), marginal
excision (simple excision), ablation, or biopsy only. Margin status is not
abstracted by SEER and thus could not be analyzed. Importantly, data on
the administration of chemotherapy are not recorded in SEER and
therefore could not be analyzed.
We then performed univariable and multivariable analyses to identify
predictors of overall survival (OS) and disease‐speciﬁc survival (DSS). OS
and DSS were estimated using the Kaplan–Meier method. Subgroup
analysis was performed testing the association of RT (predictor variable)
with both OS and DSS (outcome variable) stratifying by histologic grade
and extent of surgical resection. Univariate analyses were compared by
the log‐rank test. Multivariate analysis was performed using a Cox
proportional hazards model, adjusting for age, sex, race, histologic
subtype, histologic grade, tumor size, extent of resection, and the
administration of RT.Models were also adjusted for multiple comparisons
and subgroups. Analyses were conducted using SAS v9.2 (Cary, NC).
Since SEER patient information is de‐identiﬁed, this study qualiﬁed as
exempt from UC Davis Institutional Review Board approval.
RESULTS
Patient and Tumor Characteristics
1,189 patients met our inclusion criteria (Fig. 1). Baseline patient and
tumor characteristics are presented in Table I. The mean age was 41,
49.3% were female, and 82.2% were white. The distribution of
histologic grade was: 41.9% high, 14.0% intermediate, 2.2% low, and
41.9% unknown. Median tumor size was 5.3 cm (range: 0.3–26.0 cm),
and the majority of tumors were located in the extremity (67.6%). 53.2%
of patients were married at the time of diagnosis, while 33.3% were
single, and 9.7% were separated, divorced, or widowed.
Table I also depicts the extent of surgery performed, including 39.7%
marginal excision and 49.5% radical surgery. RT was administered to
684 patients (57.5%) with 526 patients (76.9%) receiving adjuvant RT,
138 patients (20.1%) receiving neoadjuvant RT, and 20 patients (2.9%)
Fig. 1. Schematic ﬂow chart depicting the inclusion and exclusion
criteria used to deﬁne our study cohort.
TABLE I. Patient and TumorCharacteristics: Synovial Sarcoma 1990–2009
(N¼ 1,189)
Variable Synovial sarcoma (N¼ 1,189)
Age at diagnosis (mean SD) 40.9 15.6
Gender
Female 586 (49.3%)
Male 603 (50.7%)
Race
White 977 (82.2%)
Black 126 (10.6%)
Asian or Pacific Islander 66 (5.6%)
Other 20 (1.7%)
Marital status at diagnosis
Married 633 (53.2%)
Separated/divorced/widowed 115 (9.7%)
Single 396 (33.3%)
Unknown 45 (3.8%)
Histologic grade
Low 26 (2.2%)
Intermediate 167 (14.0%)
High 498 (41.9%)
Unknown 498 (41.9%)
Tumor location
Extremity 804 (67.6%)
GI/GU/GYN 15 (1.3%)
Head and neck 95 (8.0%)
Retroperitoneal 3 (0.3%)
Thoracic 76 (6.4%)
Trunk 183 (15.4%)
Unknown 12 (1.0%)
Tumor Size, cm (median, range) 5.3 (0.3–26.0)
SEER stage
Localized 782 (65.8%)
Regional 334 (28.1%)
Unstaged 73 (6.1%)
Lymph node sampling 436 (36.7%)
Positive lymph nodes 17 (3.9%)
Radiotherapy
Yes 684 (57.5%)
No 505 (42.5%)
Type of surgery
Marginal excision 472 (39.7%)
Ablation 104 (8.7%)
Biopsy 8 (0.7%)
Radical resection 589 (49.5%)
Surgery NOS 16 (1.3%)
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receiving intra‐operative RT. The details of RT treatment, including total
dosage, treatment volume, and fractions, were not available for analysis.
Patient and Tumor Characteristics Among RT
and Non‐RT Cohorts
A comparison of the patients receiving RT and those not receiving
RT is depicted in Table II. Although patients receiving RT were
slightly younger than those not receiving RT (39.7 15.0 years vs.
42.5 16.2 years, P¼ 0.003), there were no other signiﬁcant
differences in demographic factors such as gender, race, or marital
status. In contrast, we observed signiﬁcant differences between the
groups for important clinical/pathologic factors such as histologic
grade, tumor location, stage of cancer, and type of surgery. For
example, RT patients were more likely to have high‐grade histology
(45.0% RT vs. 37.6% non‐RT, P¼ 0.003). In addition, RT patients
were more likely to have primary tumors located on the extremity
(71.3% vs. 62.6%, P< 0.0001). Although RT patients were more
likely to have localized disease (68.1 vs. 61.6%, P¼ 0.001), rates of
regionally advanced disease were comparable (27.9% RT vs. 28.2%
non‐RT). Similarly, ablative procedures were more common among
RT patients than non‐RT patients (10.1% vs. 6.9%, P¼ 0.003), while
marginal excisions (38.6% vs. 41.2%) and radical resections (50.3%
vs. 48.5%) were relatively similar. Median tumor size for RT patients
was 5.5 cm (range, 0.3–23.0 cm) compared to 5.0 cm (range, 0.5–
26.0 cm) for non‐RT patients, a slight difference which was not
statistically signiﬁcant (P¼ 0.326).
Oncologic Outcome
With a median follow up of 49 months, the ﬁve‐year OS and DSS among
all patients were 69.1 3.0% and 72.3 3.0%, respectively.Median survival
was not reached. Among patients receiving RT (Fig. 2A), we observed an
approximate 8% improvement in ﬁve‐year OS from 64.1 4.8%without RT
to 72.5 3.8% with RT (P¼ 0.003). Similarly, as depicted in Figure 2B, we
observed an approximate 8% improvement in ﬁve‐year DSS from
67.7 4.8% without RT to 75.4 3.8% with RT (P¼ 0.015).
Predictors of Overall and Disease Specific Survival
On multivariate analysis (Table III), we observed that age at
diagnosis (HR¼ 1.02, 95% CI 1.01–1.03) male sex (HR¼ 1.63, CI
TABLE II. Patient and Tumor Characteristics Among RT and Non‐RT
Cohorts
Variable RT (N¼ 684) No RT (N¼ 505) P‐value
Age at diagnosis (mean SD) 39.7 15.0 42.5 16.2 0.003
Gender 1.000
Female 337 (49.3%) 249 (49.3%)
Male 347 (50.7%) 256 (50.7%)
Race 0.140
Asian or Pacific Islander 38 (5.6%) 28 (5.5%)
Black 61 (8.9%) 65 (12.9%)
White 575 (84.1%) 402 (79.6%)
Other 10 (1.5%) 10 (2.0%)
Histologic grade 0.003
Low 16 (2.3%) 10 (2.0%)
Intermediate 105 (15.4%) 62 (12.3%)
High 308 (45.0%) 190 (37.6%)
Unknown 255 (37.3%) 243 (48.1%)
Tumor location <0.0001
Extremity 488 (71.3%) 316 (62.6%)
GI/GU/GYN 3 (0.4%) 12 (2.4%)
Head and neck 63 (9.2%) 32 (6.3%)
Retroperitoneal 2 (0.3%) 1 (0.2%)
Thoracic 17 (2.5%) 60 (11.9%)
Trunk 107 (15.6%) 76 (15.0%)
Unknown 4 (0.6%) 8 (1.6%)
SEER Stage 0.001
Localized 466 (68.1%) 316 (61.6%)
Regional 191 (27.9%) 143 (28.3%)
Unstaged 27 (3.9%) 46 (9.1%)
Marital status at diagnosis 0.600
Married 370 (54.1%) 263 (52.1%)
Separated/divorced/widowed 68 (9.9%) 47 (9.3%)
Single 224 (32.8%) 172 (34.1%)
Unknown 22 (3.2%) 23 (4.6%)
Type of surgery 0.003
Marginal excision 264 (38.6%) 208 (41.2%)
Ablation 69 (10.1%) 35 (6.9%)
Biopsy 0 (0.0%) 8 (1.6%)
Radical resection 344 (50.3%) 245 (48.5%)
Surgery NOS 7 (1.0%) 9 (1.8%)
Tumor size, cm
(median, range)
5.5 (0.3–23.0) 5.0 (0.5–26.0) 0.326
Fig. 2. A: Kaplan–Meier curve depicting overall survival among patients with synovial sarcoma undergoing surgical resection stratiﬁed by receipt
of radiation therapy (N¼ 1,189). B: Kaplan–Meier curve depicting disease‐speciﬁc survival among patients with synovial sarcoma undergoing
surgical resection stratiﬁed by receipt of radiation therapy.
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1.22–2.17), African American race (HR¼ 2.14, 95% CI 1.43–3.22),
tumor location, regionally advanced disease (HR¼ 1.61, 95% CI 1.19–
2.19), and larger tumor size (HR¼ 1.13, 95% CI 1.10–1.16) predicted
worse OS (P< 0.001). Importantly, the administration of RT
(HR¼ 0.65, 95% CI 0.48–0.88) was associated with statistically
superior OS (P¼ 0.005).
Similarly, we observed that male sex (HR¼ 1.73, 95% CI 1.27–
2.35), African American race (HR¼ 2.43, 95% CI 1.61–3.67), tumor
location, regionally advanced disease (HR¼ 1.83, 95% CI 1.32–2.54),
and larger tumor size (HR¼ 1.13, 95% CI 1.10–1.17) predicted
statistically worse DSS (P< 0.001). Notably, RT administration
(HR¼ 0.62, 95% CI 0.45–0.86) was again predictive of statistically
superior DSS (P¼ 0.003).
Subgroup Analyses
In order to reduce potential confounding from limited follow up
which can correlate with early recurrence/progression following
operation [22], we performed subgroup analyses excluding 55 (4.6%
of total) patients with fewer than six months of follow‐up time. Using
this approach, we observed similar improvements in oncologic outcome
with the addition of RT. The ﬁve‐year OS was improved by 7.3%
following RT (P¼ 0.01), and the ﬁve‐year DSS in was improved by
6.9% with RT (P¼ 0.04). We also excluded patients who only received
biopsy procedures only (N¼ 8) since these may have represented
patients with unresectable disease. Again, OS and DSSwere statistically
better with the addition of RT (P¼ 0.007 and P¼ 0.017, respectively).
We then analyzed OS and DSS among patients with adverse
pathologic features and observed consistent improvement in oncologic
outcome among patients receiving RT. For example, as depicted in
Figure 3A, among patients with high‐grade tumors, ﬁve‐year OS
improved by approximately 13.3% from 50.3 8.4% without RT to
63.6 6.4% with RT (P¼ 0.006), and ﬁve‐year DSS (Fig. 3B)
improved by 9.8% from 56.7 8.4% without RT to 66.5 6.2% with
RT (P¼ 0.02). Similarly, for patients undergoing radical surgery, ﬁve‐
year OS (Fig. 4A) improved by approximately 10.5% from 58.5 7.4%
without RT to 69.0 5.8% with RT (P¼ 0.008), and ﬁve‐year DSS
(Fig. 4B) improved by 10.2% from 61.7 7.2% without RT to
71.9 5.6% with RT (P¼ 0.01). Finally, among patients with
regionally advanced disease (data not shown), ﬁve‐year OS improved
by approximately 16% from 42.6 9.8% without RT to 58.1 7.8%
with RT (P¼ 0.007), and ﬁve‐year DSS improved by 13.4% from
46.2 10% without RT to 59.6 7.8% with RT (P¼ 0.042).
DISCUSSION
We analyzed a large national database of synovial sarcoma patients to
identify predictors of oncologic outcomes as well as the impact of RT on
OS and DSS. We observed a statistically signiﬁcant improvement in OS
and DSS among patients receiving RT, and this association was
TABLE III. Cox Proportional Hazards Multivariable Analysis of Clinicopathologic Variables and Predictors of Overall and Disease‐Speciﬁc Survival for
Synovial Sarcoma Patients Undergoing Surgery (N¼ 1,189)
Variable (predictor)
Hazard ratio for
overall survival in
synovial sarcoma patients
(95% confidence interval) P‐value
Hazard ratio for
disease‐specific
survival in synovial sarcoma
patients (95% confidence interval) P‐value
Age at diagnosis 1.02 (1.01–1.03) <0.001 1.01 (0.99–1.02) 0.391
Male 1.63 (1.22–2.17) <0.001 1.73 (1.27–2.35) <0.001
Race 0.002 <0.001
White 1.00 (referent) 1.00 (referent)
Black 2.14 (1.43–3.22) 2.43 (1.61–3.67)
Asian or Pacific Islander 0.83 (0.43–1.59) 0.66 (0.31–1.41)
Other 0.54 (0.07–3.94) 0.66 (0.09–4.92)
Anatomic site <0.001 <0.001
Extremity 1.00 (referent) 1.00 (referent)
Head & neck 1.88 (1.09–3.24) 1.71 (0.94–3.13)
Thoracic 2.60 (1.54–4.38) 2.68 (1.52–4.72)
Trunk 1.80 (1.25–2.58) 1.88 (1.28–2.76)
Abdominal 2.20 (0.78–6.17) 2.45 (0.87–6.91)
Grade 1.00 (referent) 0.412 1.00 (referent) 0.226
Low 0.83 (0.34–2.02) 0.80 (0.30–2.13)
Intermediate 0.95 (0.41–2.23) 1.09 (0.43–2.76)
High 0.73 (0.31–1.70) 0.78 (0.31–1.96)
Unknown
SEER stage <0.001 <0.001
Localized 1.00 (referent) 1.00 (referent)
Regional 1.61 (1.19–2.19) 1.83 (1.32–2.54)
Unstaged 4.88 (2.31–10.3) 3.73 (1.51–9.19)
Type of surgery <0.001 <0.001
Marginal 1.00 (referent) 1.00 (referent)
Ablation 0.76 (0.46–1.24) 0.74 (0.43–1.28)
Biopsy 44.6 (8.91–223.3) 30.2 (3.56–256.8)
Radical 1.19 (0.86–1.64) 1.17 (0.83–1.65)
Surgery NOS 6.01 (2.06–17.5) 5.16 (1.53–17.4)
Radiation 0.005 0.003
No 1.00 (referent) 1.00 (referent)
Yes 0.65 (0.48–0.88) 0.62 (0.45–0.86)
Tumor size in cm 1.13 (1.10–1.16) <0.001 1.13 (1.10–1.17) <0.001
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consistently observed in all main subgroups of patients with adverse
clinical or pathologic features.
The strengths of our study primarily relate to the large sample size
from a population‐based database. These factors not only provide greater
statistical power to detect clinically meaningful differences but also
support the generalizability of our ﬁndings. Although there are missing/
absent data in SEER (such as the presence of SYT‐SSX gene
translocation or the administration of chemotherapy) which we are
not able to retrospectively ascertain, the SEER registry nevertheless
represents the only comprehensive source of population‐based cancer
data in the US that includes stage of cancer at the time of diagnosis, cause
of death, and patient survival time (http://seer.cancer.gov/).
Furthermore, the characteristics of the patients in this analysis are
comparable to those of synovial sarcoma patients reported in the largest
single institution series on which current synovial sarcoma‐speciﬁc
outcomes data are based [7,8,10,11,23,24]. For example, similar to
Eilber et al. and Ferrari et al., the patients in our cohort were
approximately 50% female, had a median age of 30–40, had maximal
tumor dimension in the intermediate range (5–10 cm), and had the
majority of tumors located on the extremity [7,13]. Furthermore, similar
to these authors, we identiﬁed tumor size to be a strong predictor of
worse oncologic outcome.We also observed stage at presentation, tumor
location, and male sex to be associated with worse oncologic outcome.
Somewhat paradoxically, we found radical surgery to be associated with
worse oncologic outcome, although we suspect this result is related to
the effect of confounding factors which are co‐linear with radical
surgery, such as high‐grade histology and regionally advanced disease.
On multivariate analysis, we found a strong association between RT
administration and OS (HR 0.65, P< 0.001) as well as DSS (HR 0.62,
P¼ 0.003). In addition, our Kaplan–Meier results show an association
between RT and improved OS and DSS for patients receiving radical
surgery, suggesting the therapeutic effect of RT is independent of the extent
of surgery performed. Similarly, we observed that RT predicted improved
OS and DSS in subgroup analyses of patients with high‐grade histology
and patients with regionally advanced disease, indicating that the
association of RT with superior OS and DSS was consistent and
reproducible across the subgroups, at least in this population‐based dataset.
These observations are consistent with the ﬁndings of Koshy et al., who
Fig. 3. A: Kaplan–Meier curve depicting overall survival among patients with high‐grade tumors stratiﬁed by receipt of radiation therapy
(N¼ 498). B: Kaplan–Meier curve depicting disease‐speciﬁc survival among patients with high‐grade tumors stratiﬁed by receipt of radiation
therapy.
Fig. 4. A: Kaplan–Meier curve depicting overall survival among patients receiving radical surgery stratiﬁed by receipt of radiation therapy
(N¼ 589). B: Kaplan–Meier curve depicting disease‐speciﬁc survival among patients receiving radical surgery stratiﬁed by receipt of radiation
therapy.
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also demonstrated an association between RT and improved overall
survival time among heterogeneous extremity STS patients [25]. However,
other studies have not reproduced these ﬁndings. Yang et al., for example,
examined the impact of adjuvant RT among extremity STS patients in a
randomized trial and failed to observe a beneﬁt in OS [26]. It is possible,
however, that this study was underpowered to detect small, but potentially
meaningful, differences in survival, particularly for speciﬁc histologic
subtypes. Twenty‐year follow up from this study, recently reported by
Beane et al., again failed to demonstrate an improvement in OS after RT,
although patients continued to experience improved local control [27]. In
contrast, Schreiber et al. demonstrated (in a retrospective analysis) that RT
is associated with improved survival in patients with high grade STS of the
extremity undergoing limb‐sparing surgery [28].
Although previous studies have evaluated the role of RT in the multi‐
modality management of synovial sarcoma, the results have been
equivocal. Some series have demonstrated improved local control and
disease‐free survival with RT [8,29], while other series have found the
opposite or mixed results [6,10]. In addition, some authors have suggested
that synovial sarcoma may be resistant to RT. Rhomberg, for example,
evaluated the radiosensitivity of numerous STS subtypes based on tumor
response to deﬁnitive RT and subsequent risk of local progression [19]. In
this series, synovial sarcomas had one of the lowest response rates to RT
with a corresponding higher rate of local tumor progression.
Although relatively few studies have focused on the role of RT in
synovial sarcoma, a larger proportion of studies have examined the role
of chemotherapy in synovial sarcoma [10,11,13,16,30–32]. Canter et al.
constructed a nomogram regarding factors associated with OS and DSS
in synovial sarcoma. This analysis observed an early survival beneﬁt to
chemotherapy, but did not identify RT as a signiﬁcant factor for
outcome [6]. In contrast, in a study of 102 patients, Al‐Hussaini et al.
observed that although chemotherapy was routinely used in the
management of localized synovial sarcoma, the occurrence of relapse
was higher in adult and pediatric patients receiving chemotherapy than
among those patients not receiving chemotherapy [16]. Al‐Hussaini
et al. identiﬁed notable differences in the treatment of adult and pediatric
patients with a large majority of pediatric patients receiving
chemotherapy (in contrast to adult patients) and the opposite
relationship for RT. This reinforces the concept that because of the
potential for overlapping toxicities, the use of RT either sequentially or
in combination with chemotherapy may limit the ability to administer
recommended doses of chemotherapy [17,18].
In a study of national practice patterns for STS, Sherman et al.
identiﬁed synovial sarcoma as a predictor of a higher likelihood to
receive adjuvant/neoadjuvant chemotherapy [2]. In addition, these
authors demonstrated increasing rates of chemotherapy administration
over time among STS patients, including synovial sarcoma patients,
with a corresponding decrease in trimodality therapy over time. This
study highlights the fact that trimodality therapy can be problematic in
adults since the prevalence of severe toxicities may limit any incremental
beneﬁts in outcome. Consequently, appropriate selection of patients for
combined modality therapy is crucial.
It is important to acknowledge the limitations that comewith our study.
The SEER database lacks data on important factors such as chemotherapy
and status of the surgical margins. In addition, not all patients in the
database have complete information. Moreover, in a retrospective study
based on local physician and institutional practices, there is likely to be
selection bias in terms of which patients received RT. Given the possibility
that patients with short follow‐up could suffer relapse and death before
receiving RT, we performed subgroup analysis excluding patients with
fewer than six months of follow up. Our largely unchanged results,
therefore, do not support “immortal time bias” in this analysis [22].
We did observe differences in the clinical and pathologic
characteristics among patients who received RT and those who did
not. Patients receiving RT were slightly younger, had higher‐grade
tumors, and were more likely to have localized disease, although the
percentages of regional diseasewere similar. Similarly, there was a slight
difference in the distribution of surgery with a modest increase in radical
surgery among patients receiving RT. Although these imbalances in
patient factors may have confounded our results, these factors did not
clearly favor the group receiving RT and the improved survival
outcomes with RT on both multivariate and multiple subgroup analyses
suggest a reproducible and consistent effect.
Despite these limitations, this study is the ﬁrst population‐based
analysis of the impact of RT focused on synovial sarcoma patients, and
the larger sample size of our study may overcome the limitations of
selection bias and lack of generalizability, which are potential
weaknesses of single‐institution studies. Although the results of our
study are appropriately viewed as hypothesis generating, it is unlikely
that a histology‐based randomized trial examining this question will be
performed given the rarity of synovial sarcoma. Therefore, outcomes
data such as these are important to inform treatment decisions and help
guide avenues for further research.
In summary, although we could not control for the use of
chemotherapy in this analysis, RT was associated with a statistically
signiﬁcant improvement in survival among synovial sarcoma patients
treated surgically. Improvements in oncologic outcome were most
pronounced for patients with adverse pathologic features, and the
improvement in OS and DSS was consistent across all subgroups.
Although further study is warranted to determine the best multi‐modality
treatment sequencing, these data support the use of RT in the
multidisciplinary approach to patients with synovial sarcoma.
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